mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Biotechnology company

Product

Home > Product

Description

Product: OС000459, selective antagonist of CRTH2 receptors

Therapeutic focus: asthma and other respiratory diseases: allergic rhinitis, conjunctivitis, atopic dermatitis, and eosinophilic esophagitis.

Status: Phase 3 clinical trials.

Partner: Oxagen, Ltd., Atopix Therapeutics (UK)

Description:  OC000459 is a safe low molecular compound that comes in one-a-day oral tablets for the treatment of moderate to severe asthma and other respiratory diseases.

OC000459’s innovative mechanism is unique in its highly selective binding to a specific receptor, blocking pathogenesis at an early stage and reducing eosinophilic inflammation which plays a key role in the development of chronic allergic respiratory diseases. Due to this mechanism, the drug is more selective with respect to a specific inflammatory response and devoid of local and systemic side effects of glucocorticoid therapy.

mbg-eleventa-001Development

Currently preclinical and 1/2 clinical trials have been successfully conducted and shown a high efficacy and safety.

At the present time the company is due to complete a phase 3 clinical trial in patients with atopic eosinophilic asthma within the drug registration procedure in Russia. 16 biggest Russian clinical sites are participating within the clinical study.

 

 

© Eleventa, 2012—2020